Compare Orchid Chemicals with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs GSK PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD GSK PHARMA ORCHID PHARMA LTD/
GSK PHARMA
 
P/E (TTM) x -0.4 226.4 - View Chart
P/BV x 0.1 11.6 1.0% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ORCHID PHARMA LTD   GSK PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
GSK PHARMA
Mar-19
ORCHID PHARMA LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1943,595 5.4%   
Low Rs351,253 2.8%   
Sales per share (Unadj.) Rs276.5184.7 149.7%  
Earnings per share (Unadj.) Rs-79.226.3 -301.3%  
Cash flow per share (Unadj.) Rs-43.529.2 -149.0%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.9126.3 42.7%  
Shares outstanding (eoy) m70.45169.40 41.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.413.1 3.2%   
Avg P/E ratio x-1.492.2 -1.6%  
P/CF ratio (eoy) x-2.683.1 -3.2%  
Price / Book Value ratio x2.119.2 11.1%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m8,067410,626 2.0%   
No. of employees `0002.85.0 56.5%   
Total wages/salary Rs m2,5275,372 47.0%   
Avg. sales/employee Rs Th6,956.16,306.7 110.3%   
Avg. wages/employee Rs Th902.51,083.1 83.3%   
Avg. net profit/employee Rs Th-1,993.0898.0 -221.9%   
INCOME DATA
Net Sales Rs m19,47731,281 62.3%  
Other income Rs m4071,023 39.8%   
Total revenues Rs m19,88432,304 61.6%   
Gross profit Rs m1,1036,009 18.3%  
Depreciation Rs m2,519486 518.4%   
Interest Rs m5,2276 87,113.3%   
Profit before tax Rs m-6,2366,540 -95.4%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511287 178.0%   
Tax Rs m-1252,373 -5.3%   
Profit after tax Rs m-5,5804,454 -125.3%  
Gross profit margin %5.719.2 29.5%  
Effective tax rate %2.036.3 5.5%   
Net profit margin %-28.714.2 -201.2%  
BALANCE SHEET DATA
Current assets Rs m11,01420,061 54.9%   
Current liabilities Rs m32,06014,543 220.4%   
Net working cap to sales %-108.117.6 -612.5%  
Current ratio x0.31.4 24.9%  
Inventory Days Days9557 167.1%  
Debtors Days Days3414 238.7%  
Net fixed assets Rs m29,44014,343 205.3%   
Share capital Rs m7051,694 41.6%   
"Free" reserves Rs m2,04319,704 10.4%   
Net worth Rs m3,80021,398 17.8%   
Long term debt Rs m9,0182 450,895.0%   
Total assets Rs m46,51039,113 118.9%  
Interest coverage x-0.21,091.0 -0.0%   
Debt to equity ratio x2.40 2,539,114.7%  
Sales to assets ratio x0.40.8 52.4%   
Return on assets %-0.811.4 -6.7%  
Return on equity %-146.920.8 -705.5%  
Return on capital %-3.731.9 -11.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,513534 1,407.0%   
Fx outflow Rs m5,6497,091 79.7%   
Net fx Rs m1,865-6,557 -28.4%   
CASH FLOW
From Operations Rs m1,6823,994 42.1%  
From Investments Rs m-9,860-1,433 687.9%  
From Financial Activity Rs m6,644-3,584 -185.4%  
Net Cashflow Rs m-1,535-1,023 150.0%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 4.6 10.2 45.1%  
FIIs % 3.3 23.8 13.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 15.4 359.1%  
Shareholders   84,811 102,036 83.1%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Extend Gains; M&M and Hero MotoCorp Surge Over 4%(12:30 pm)

Share markets in India have extended early gains and are presently trading higher, tracking gains in Asian peers and Wall Street.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

This is How You Should Trade Intraday(Fast Profits Daily)

Jun 19, 2020

In this video, I'll show you how to trade the market intraday like a professional trader.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS